A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Trial Profile

A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Aflibercept (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AMOR
  • Sponsors Sanofi
  • Most Recent Events

    • 18 Mar 2016 Status changed from completed to discontinued due to safety reasons.
    • 21 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 04 Jun 2014 Planned End Date changed from 1 Jun 2016 to 1 Feb 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top